BDTX (Black Diamond Therapeutics) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


BDTX Black Diamond Therapeutics Inc BDTX
38 GF Score
Price $1.71
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Black Diamond Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

BDTX vs GUTS, ALPS, ONCY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Black Diamond Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Black Diamond Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Black Diamond Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Black Diamond Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


BDTX
38GF Score
Black Diamond Therapeutics Inc BDTX
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
38GF Score

Get the complete analysis for BDTX

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.71
Price